⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177368 | 0.78 | — | — | |
| SCHEMBL2480173 | 0.76 | — | — | |
| SCHEMBL7858661 | 0.76 | — | — | |
| SCHEMBL5466454 | 0.76 | — | — | |
| SCHEMBL8465606 | 0.76 | — | — | |
| SCHEMBL818858 | 0.74 | GABRA1 (0.30) | — | |
| SCHEMBL5178222 | 0.74 | ALDH1A1 (0.39) | — | |
| SCHEMBL23248041 | 0.73 | ESR1 (0.31) | — | |
| SCHEMBL2480444 | 0.73 | GABRA1 (0.30) | — | |
| SCHEMBL8466418 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110237071-A | Pharmaceutical preparation and its application | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | claimed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | claimed |
| CN-102091330-A | Pharmaceutical compositions comprising valsartan and NEP inhibitors | NOVARTIS AG | 2011-06-15 | — | — | CN | claimed |
| CN-101300030-A | Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent | NOVARTIS AG (CH) | 2008-11-05 | — | — | CN | claimed |
| CN-101151027-A | Combination of organic compounds | NOVARTIS AG (CH) | 2008-03-26 | — | — | CN | claimed |
| CN-1615134-A | Pharmaceutical composition comprising valsartan and NEP inhibitor | NOVARTIS AG (CH) | 2005-05-11 | — | — | CN | claimed |
| CN-110237071-A | Pharmaceutical preparation and its application | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-109803657-A | Pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-05-24 | — | — | CN | disclosed |
| US-20190071416-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-03-07 | — | — | US | disclosed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017061957-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-04-13 | — | — | WO | disclosed |
| CN-104602711-A | NEP inhibitors for the treatment of diseases characterized by atrial augmentation or remodeling | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| CN-101478969-A | Use of PKC inhibitors in diabetic complications | NOVARTIS AG (CH) | 2009-07-08 | — | — | CN | disclosed |
| CN-101300030-A | Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent | NOVARTIS AG (CH) | 2008-11-05 | — | — | CN | disclosed |
| CN-101151027-A | Combination of organic compounds | NOVARTIS AG (CH) | 2008-03-26 | — | — | CN | disclosed |
| CN-101098689-A | Pharmaceutical combination of angiotensin receptor antagonist and NEP inhibitor | NOVARTIS AG (CH) | 2008-01-02 | — | — | CN | disclosed |
| CN-101043916-A | Combination of organic compounds | NOVARTIS AG (CH) | 2007-09-26 | — | — | CN | disclosed |
| CN-1615134-A | Pharmaceutical composition comprising valsartan and NEP inhibitor | NOVARTIS AG (CH) | 2005-05-11 | — | — | CN | disclosed |